Is Volitionrx Ltd (VNRX) overvalued? · rev $1.2M
Volitionrx Ltd (VNRX) is a medical devices company listed on AMEX.
This page asks whether Volitionrx Ltd (VNRX) looks expensive on cached numbers — not a short thesis.
Latest reported VNRX revenue for 2024-12-31 was $1.2M. Net income was -$27.3M. Revenue was up 59.1% from 2023-12-31 to 2024-12-31. VNRX currently screens at market cap $15.9M.
VNRX currently screens at market cap $15.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VNRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VNRX stock page for the full model, not this heading.
Not investment advice.